Figure 7.
Serum levels of ovalbumin (OVA) -specific antibody in mice adoptively transferred OVA-loaded bone-marrow-derived dendritic cells (BMDC) with or without pre-exposure to recombinant cysteine protease inhibitor from Heligmosomoides polygyrus (rHp-CPI). Normal BMDC or BMDC pre-treated with rHp-CPI for 2 hr were incubated with OVA for 4 hr. The cells were washed and adoptively transferred intravenously (5 × 105/mouse) to recipient mice. The mice were boosted with OVA antigen 4 weeks later. Levels of OVA-specific antibodies in serum samples collected immediately before boosting (a) and 4 weeks after boosting (b) were determined by ELISA. Antibody levels are expressed as endpoint titres. Data shown are means ± SD of three or four mice per group from one of two independent experiments. Statistically significant differences, *P < 0·05 and **P < 0·01, are indicated.